Engineering the Future of Therapeutics
At Nanomedsyn, we develop AMFA glycovectors designed to target the mannose 6-phosphate receptor (M6PR) and enhance intracellular delivery of therapeutic antibodies, enzymes, or nanoparticles. Our platform enables efficient internalization and precise routing to lysosomes, unlocking new opportunities for first-in-class drug discovery.
We collaborate with pharma, biotech, and academic partners to develop breakthrough therapeutics targeting challenges once considered unreachable. Together, letʼs shape the future of medicine!
AMFA Glycovectors Platform
A modular and robust targeting technology engineered to:
- Improve cellular uptake
- Enhance lysosomal trafficking
- Deliver biologics, enzymes, antibodies, and nanoparticles
- Access previously unreachable therapeutic targets
Therapeutic Antibodies & Targeted Protein Degradation
Therapeutic antibodies are evolving with Targeted Protein Degradation (TPD), enabling the removal—not only inhibition—of disease‑driving proteins. Our glycovectors technology help reach previously undruggable targets with precision.
Enzyme Replacement Therapy (ERT)
Enhanced ERT solutions improve lysosomal targeting and tissue uptake for rare disorders like Pompe disease. Our engineered systems support more effective and long-lasting therapeutic responses.
Nanoparticles for Precision Delivery
Advanced nanoparticle systems remodelled with our glycovectors enable precise delivery of RNA, enzymes, and biologics into difficult tissues, unlocking new possibilities for treating complex and undruggable diseases.